\-\ Texto\\:\\ \ \(0\)\
\-\ patient\\ was\\ alert\\ and\\ oriented\\.\\ \\ physical\\ exam\\ was\\ significant\\ for\\ 4\\/5\\ strength\\ in\\ right\\ ue\\ and\\ 2\\/5\\ strength\\ in\\ right\\ le\\.\\ \\ no\\ other\\ neurologic\\ deficits\\ were\\ noted\\.\\ \\ hiv\\ test\\ was\\ negative\\.\\ tee\\ demonstrated\\ no\\ vegetations\\.\\ \\ coagulation\\ panel\\ was\\ within\\ normal\\ limits\\.\\ \\ extensive\\ laboratory\\ work\\ up\\ failed\\ to\\ identify\\ any\\ abnormalities\\.\ \(0\)\
\-\ patient\\ was\\ treated\\ with\\ whole\\ brain\\ xrt\\,\\ but\\ could\\ not\\ tolerate\\ the\\ side\\ effects\\.\\ \\ he\\ was\\ discharged\\ to\\ home\\ for\\ palliative\\ care\\.\ \(0\)\
\-\ patient\\ has\\ multiple\\ ring\\-enhancing\\ lesions\\ with\\ increased\\ t2\\ signal\\ within\\ the\\ deep\\ cerebral\\ white\\ matter\\ involving\\ both\\ hemispheres\\.\\ \\ three\\ of\\ the\\ lesions\\ are\\ centered\\ on\\ the\\ periventricular\\ area\\.\\ \\ a\\ fourth\\ lesion\\ is\\ present\\ on\\ the\\ superior\\ portion\\ of\\ the\\ corpus\\ collosum\\ and\\ a\\ fifth\\ cystic\\ lesion\\ in\\ the\\ posterior\\ parieto\\-occiptial\\ area\\.\\ \\ no\\ deviation\\ of\\ the\\ midline\\ is\\ appreciated\\.\ \(0\)\
\-\ brain\\ biopsy\\ confirmed\\ patient\\ has\\ glioblastoma\\ multiforme\\.\ \(0\)\
\-\ lymphoma\\,\\ glioblastoma\\ multiforme\\,\\ tumefactive\\ multiple\\ sclerosis\\,\\ toxoplasmosis\\,\\ neurocystercercosis\\,\\ cryptococcus\ \(0\)\
\-\ patient\\ presented\\ with\\ right\\-sided\\ weakness\\ and\\ tonic\\-clonic\\ activity\\ in\\ his\\ right\\ upper\\ and\\ lower\\ extremity\\.\ \(0\)\
\-\ glioblastome\\ multiforme\\ \\(gbm\\)\\ is\\ the\\ most\\ common\\ type\\ of\\ primary\\ brain\\ tumor\\ in\\ adult\\ patients\\.\\ \\ it\\ has\\ an\\ equal\\ distribution\\ among\\ men\\ and\\ women\\ with\\ a\\ peak\\ incidence\\ in\\ the\\ fifth\\ decade\\ of\\ life\\.\\ \\ it\\ is\\ the\\ most\\ aggressive\\ type\\ of\\ astrocytoma\\ and\\ has\\ a\\ poor\\ prognosis\\.\\ \\ the\\ average\\ survival\\ after\\ diagnosis\\ is\\ eight\\ months\\.\ \(0\)\
\-\ some\\ patients\\ \\(like\\ this\\ one\\)\\ have\\ multicentric\\ gbm\\ which\\ is\\ an\\ uncommon\\ and\\ often\\ more\\ aggressive\\ form\\ of\\ this\\ disease\\,\\ occurring\\ in\\ less\\ than\\ 1\\ \\-\\ 15\\%\\ of\\ patients\\ with\\ gbm\\.\\ \\ it\\ is\\ characterized\\ in\\ this\\ patient\\ by\\ its\\ presence\\ in\\ both\\ cerebral\\ hemispheres\\.\ \(0\)\
\-\ the\\ two\\ most\\ common\\ presenting\\ symptoms\\ are\\ headache\\ and\\ seizure\\.\\ \\ hemiparesis\\ was\\ the\\ most\\ common\\ neurologic\\ deficit\\ at\\ presentation\\ occurring\\ in\\ up\\ to\\ 83\\%\\ of\\ patients\\.\\ \\ this\\ patient\\ denied\\ headaches\\,\\ but\\ did\\ have\\ seizures\\ and\\ hemiparesis\\.\\ \\ the\\ imaging\\ finding\\ of\\ ring\\-enhancing\\ lesions\\ is\\ not\\ specific\\ enough\\ to\\ be\\ diagnostic\\.\\ \\ ultimately\\,\\ a\\ biopsy\\ of\\ the\\ lesions\\ was\\ required\\ for\\ definitive\\ diagnosis\\.ct\\ or\\ mri\\ can\\ be\\ used\\ to\\ image\\ patients\\ with\\ suspected\\ brain\\ lesions\\.\\ \\ however\\,\\ mri\\ is\\ more\\ sensitive\\ and\\ ct\\ can\\ miss\\ lesions\\ in\\ the\\ posterior\\ fossa\\.\\ \\ in\\ a\\ small\\ study\\ looking\\ at\\ imaging\\ in\\ patients\\ with\\ multifocal\\ glioblastoma\\ multiforme\\,\\ it\\ was\\ found\\ that\\ the\\ lesions\\ were\\ always\\ hypointense\\ or\\ isodense\\ on\\ ct\\ and\\ hyperintense\\ on\\ t\\-2\\ weighted\\ mri\\.\\ \\ ring\\-like\\ enhancement\\ was\\ also\\ a\\ common\\ finding\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ multiforme\\:\\ 0\\.22749224875092472\ \(0\)\
\-\ lesions\\:\\ 0\\.21940495544838262\ \(0\)\
\-\ the\\:\\ 0\\.1960176938970697\ \(0\)\
\-\ was\\:\\ 0\\.19020245482539783\ \(0\)\
\-\ patients\\:\\ 0\\.18421160982301427\ \(0\)\
\-\ in\\:\\ 0\\.1764973023688919\ \(0\)\
\-\ gbm\\:\\ 0\\.17311660362776046\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.1632733382606364\ \(0\)\
\-\ brain\\:\\ 0\\.13608991637005544\ \(0\)\
\-\ and\\:\\ 0\\.1353293272777674\ \(0\)\
\-\ is\\:\\ 0\\.13451385736600455\ \(0\)\
\-\ patient\\:\\ 0\\.12425562965385986\ \(0\)\
\-\ common\\:\\ 0\\.12380317196872033\ \(0\)\
\-\ hemiparesis\\:\\ 0\\.12034457578732898\ \(0\)\
\-\ of\\:\\ 0\\.11748290746398533\ \(0\)\
\-\ most\\:\\ 0\\.11361182791361163\ \(0\)\
\-\ it\\:\\ 0\\.11174658517584939\ \(0\)\
\-\ occurring\\:\\ 0\\.11012501783682083\ \(0\)\
\-\ fifth\\:\\ 0\\.10854272895005054\ \(0\)\
\-\ hemispheres\\:\\ 0\\.10598763335884902\ \(0\)\
\-\ has\\:\\ 0\\.09971474464723683\ \(0\)\
\-\ aggressive\\:\\ 0\\.09438935007181092\ \(0\)\
\-\ strength\\:\\ 0\\.09143970868287647\ \(0\)\
\-\ neurocystercercosis\\:\\ 0\\.08727876368953658\ \(0\)\
\-\ glioblastome\\:\\ 0\\.08727876368953658\ \(0\)\
\-\ neurologic\\:\\ 0\\.08721966838196363\ \(0\)\
\-\ mri\\:\\ 0\\.08404329130452264\ \(0\)\
\-\ like\\:\\ 0\\.08112612207506156\ \(0\)\
\-\ vegetations\\:\\ 0\\.07851224683063678\ \(0\)\
\-\ tee\\:\\ 0\\.07676790418285523\ \(0\)\
\-\ biopsy\\:\\ 0\\.07651153597641583\ \(0\)\
\-\ cerebral\\:\\ 0\\.07562138509492555\ \(0\)\
\-\ this\\:\\ 0\\.07501306408414589\ \(0\)\
\-\ with\\:\\ 0\\.07480652039203664\ \(0\)\
\-\ miss\\:\\ 0\\.07401553569278722\ \(0\)\
\-\ type\\:\\ 0\\.0732232168389464\ \(0\)\
\-\ collosum\\:\\ 0\\.07288865867454854\ \(0\)\
\-\ cryptococcus\\:\\ 0\\.07288865867454854\ \(0\)\
\-\ multicentric\\:\\ 0\\.07288865867454854\ \(0\)\
\-\ right\\:\\ 0\\.07237669113716566\ \(0\)\
\-\ finding\\:\\ 0\\.07174703119652645\ \(0\)\
\-\ area\\:\\ 0\\.07071012959229477\ \(0\)\
\-\ to\\:\\ 0\\.06821935335009123\ \(0\)\
\-\ ue\\:\\ 0\\.06738392169441254\ \(0\)\
\-\ on\\:\\ 0\\.06593144820689495\ \(0\)\
\-\ tolerate\\:\\ 0\\.06524901883388741\ \(0\)\
\-\ coagulation\\:\\ 0\\.06350467618610586\ \(0\)\
\-\ xrt\\:\\ 0\\.06273887585457046\ \(0\)\
\-\ ct\\:\\ 0\\.062332685724895\ \(0\)\
\-\ tumefactive\\:\\ 0\\.062029855491638634\ \(0\)\
\-\ toxoplasmosis\\:\\ 0\\.06136977332558074\ \(0\)\
\-\ eight\\:\\ 0\\.06105606008525347\ \(0\)\
\-\ looking\\:\\ 0\\.06105606008525347\ \(0\)\
\-\ isodense\\:\\ 0\\.06105606008525347\ \(0\)\
\-\ both\\:\\ 0\\.060868417736546596\ \(0\)\
\-\ le\\:\\ 0\\.06017228789366449\ \(0\)\
\-\ more\\:\\ 0\\.05993602541607561\ \(0\)\
\-\ palliative\\:\\ 0\\.05885963034626378\ \(0\)\
\-\ identify\\:\\ 0\\.058150609983331956\ \(0\)\
\-\ enough\\:\\ 0\\.058150609983331956\ \(0\)\
\-\ among\\:\\ 0\\.057705534542586825\ \(0\)\
\-\ decade\\:\\ 0\\.057490527817274054\ \(0\)\
\-\ imaging\\:\\ 0\\.05736297692917984\ \(0\)\
\-\ panel\\:\\ 0\\.05728024689923375\ \(0\)\
\-\ whole\\:\\ 0\\.05728024689923375\ \(0\)\
\-\ can\\:\\ 0\\.05727941874724082\ \(0\)\
\-\ ultimately\\:\\ 0\\.0570744885039099\ \(0\)\
\-\ centered\\:\\ 0\\.05687306218773118\ \(0\)\
\-\ average\\:\\ 0\\.05687306218773118\ \(0\)\
\-\ effects\\:\\ 0\\.05667578928886473\ \(0\)\
\-\ diagnosis\\:\\ 0\\.05658353139478371\ \(0\)\
\-\ posterior\\:\\ 0\\.05644334913222875\ \(0\)\
\-\ were\\:\\ 0\\.05626461079127412\ \(0\)\
\-\ periventricular\\:\\ 0\\.05610726185619577\ \(0\)\
\-\ peak\\:\\ 0\\.05592502021985329\ \(0\)\
\-\ men\\:\\ 0\\.0555706316820617\ \(0\)\
\-\ 83\\:\\ 0\\.05539824149326395\ \(0\)\
\-\ failed\\:\\ 0\\.05506250891841041\ \(0\)\
\-\ deviation\\:\\ 0\\.05489895969432176\ \(0\)\
\-\ have\\:\\ 0\\.05452732273165888\ \(0\)\
\-\ up\\:\\ 0\\.05399329384098269\ \(0\)\
\-\ but\\:\\ 0\\.05397574703254806\ \(0\)\
\-\ hiv\\:\\ 0\\.05397235899567065\ \(0\)\
\-\ sensitive\\:\\ 0\\.05368241569708216\ \(0\)\
\-\ multiple\\:\\ 0\\.05338853220545018\ \(0\)\
\-\ survival\\:\\ 0\\.05326333863273883\ \(0\)\
\-\ no\\:\\ 0\\.053242396240405214\ \(0\)\
\-\ multifocal\\:\\ 0\\.05299381667942451\ \(0\)\
\-\ lesion\\:\\ 0\\.05232981209187896\ \(0\)\
\-\ equal\\:\\ 0\\.0522280163478891\ \(0\)\
\-\ deficit\\:\\ 0\\.051633576954800434\ \(0\)\
\-\ always\\:\\ 0\\.05151899598495727\ \(0\)\
\-\ adult\\:\\ 0\\.05034163126840334\ \(0\)\
\-\ within\\:\\ 0\\.05027196381632101\ \(0\)\
\-\ alert\\:\\ 0\\.050241448189356504\ \(0\)\
\-\ characterized\\:\\ 0\\.050142303295610285\ \(0\)\
\-\ definitive\\:\\ 0\\.04985088797661293\ \(0\)\
\-\ corpus\\:\\ 0\\.04975568921475543\ \(0\)\
\-\ for\\:\\ 0\\.04962461976360417\ \(0\)\
\-\ uncommon\\:\\ 0\\.04938409312443215\ \(0\)\
\-\ denied\\:\\ 0\\.049293406221478604\ \(0\)\
\-\ oriented\\:\\ 0\\.04920357085131264\ \(0\)\
\-\ appreciated\\:\\ 0\\.04920357085131264\ \(0\)\
\-\ women\\:\\ 0\\.049114571171117824\ \(0\)\
\-\ fourth\\:\\ 0\\.04893901768368702\ \(0\)\
\-\ home\\:\\ 0\\.04826734569594708\ \(0\)\
\-\ prognosis\\:\\ 0\\.0480271473907611\ \(0\)\
\-\ hypointense\\:\\ 0\\.0480271473907611\ \(0\)\
\-\ form\\:\\ 0\\.04771598511608781\ \(0\)\
\-\ incidence\\:\\ 0\\.0469796683105927\ \(0\)\
\-\ deficits\\:\\ 0\\.04690905989691513\ \(0\)\
\-\ discharged\\:\\ 0\\.046838968765637645\ \(0\)\
\-\ distribution\\:\\ 0\\.046295992059510606\ \(0\)\
\-\ poor\\:\\ 0\\.04603563867098856\ \(0\)\
\-\ seizure\\:\\ 0\\.045414160713171926\ \(0\)\
\-\ life\\:\\ 0\\.044774157036390004\ \(0\)\
\-\ suspected\\:\\ 0\\.044718043112315115\ \(0\)\
\-\ seizures\\:\\ 0\\.04455164941172905\ \(0\)\
\-\ work\\:\\ 0\\.044496821773839026\ \(0\)\
\-\ test\\:\\ 0\\.044388100187640396\ \(0\)\
\-\ be\\:\\ 0\\.04427853093396126\ \(0\)\
\-\ hyperintense\\:\\ 0\\.04341256129211536\ \(0\)\
\-\ limits\\:\\ 0\\.043124075216380744\ \(0\)\
\-\ not\\:\\ 0\\.04309054326612858\ \(0\)\
\-\ fossa\\:\\ 0\\.04284403385944641\ \(0\)\
\-\ presenting\\:\\ 0\\.04275247912605747\ \(0\)\
\-\ deep\\:\\ 0\\.04248295717274314\ \(0\)\
\-\ extensive\\:\\ 0\\.04204996941096352\ \(0\)\
\-\ an\\:\\ 0\\.041739290717170925\ \(0\)\
\-\ diagnostic\\:\\ 0\\.04159527752893381\ \(0\)\
\-\ matter\\:\\ 0\\.04155499369414122\ \(0\)\
\-\ are\\:\\ 0\\.04141815262860153\ \(0\)\
\-\ specific\\:\\ 0\\.041356080154504475\ \(0\)\
\-\ at\\:\\ 0\\.041228025368419366\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.04119987429071171\ \(0\)\
\-\ midline\\:\\ 0\\.04104617786687787\ \(0\)\
\-\ used\\:\\ 0\\.04085746570091382\ \(0\)\
\-\ headaches\\:\\ 0\\.040709130998921296\ \(0\)\
\-\ weighted\\:\\ 0\\.040709130998921296\ \(0\)\
\-\ its\\:\\ 0\\.040383554897026386\ \(0\)\
\-\ confirmed\\:\\ 0\\.04024233614674051\ \(0\)\
\-\ activity\\:\\ 0\\.0400686944180589\ \(0\)\
\-\ weakness\\:\\ 0\\.03983077176172199\ \(0\)\
\-\ could\\:\\ 0\\.03969742609616707\ \(0\)\
\-\ laboratory\\:\\ 0\\.039631443788928924\ \(0\)\
\-\ abnormalities\\:\\ 0\\.039533315783808684\ \(0\)\
\-\ extremity\\:\\ 0\\.03930819018221841\ \(0\)\
\-\ presence\\:\\ 0\\.03921330613217911\ \(0\)\
\-\ did\\:\\ 0\\.039150568880301766\ \(0\)\
\-\ portion\\:\\ 0\\.0390263152296043\ \(0\)\
\-\ care\\:\\ 0\\.03899550233138128\ \(0\)\
\-\ required\\:\\ 0\\.03896478835113974\ \(0\)\
\-\ sclerosis\\:\\ 0\\.03887323361775079\ \(0\)\
\-\ involving\\:\\ 0\\.03822733588220588\ \(0\)\
\-\ or\\:\\ 0\\.03797197561862569\ \(0\)\
\-\ side\\:\\ 0\\.03770258522062224\ \(0\)\
\-\ headache\\:\\ 0\\.037622298903645296\ \(0\)\
\-\ presentation\\:\\ 0\\.03756914656344441\ \(0\)\
\-\ less\\:\\ 0\\.03712889096996924\ \(0\)\
\-\ 15\\:\\ 0\\.036879075298860926\ \(0\)\
\-\ three\\:\\ 0\\.03663561695560659\ \(0\)\
\-\ study\\:\\ 0\\.03639820039023377\ \(0\)\
\-\ white\\:\\ 0\\.0360076401774902\ \(0\)\
\-\ often\\:\\ 0\\.03561077881417781\ \(0\)\
\-\ superior\\:\\ 0\\.03548206750127898\ \(0\)\
\-\ found\\:\\ 0\\.0353131024629646\ \(0\)\
\-\ any\\:\\ 0\\.035271323371995095\ \(0\)\
\-\ image\\:\\ 0\\.03490330120649057\ \(0\)\
\-\ some\\:\\ 0\\.03433863175065867\ \(0\)\
\-\ treated\\:\\ 0\\.033985962267157666\ \(0\)\
\-\ negative\\:\\ 0\\.033787573701958125\ \(0\)\
\-\ primary\\:\\ 0\\.03355829792608313\ \(0\)\
\-\ demonstrated\\:\\ 0\\.03354088682641253\ \(0\)\
\-\ his\\:\\ 0\\.03309897468430046\ \(0\)\
\-\ cystic\\:\\ 0\\.03286921483867259\ \(0\)\
\-\ lymphoma\\:\\ 0\\.032503334639063824\ \(0\)\
\-\ two\\:\\ 0\\.03241014497409644\ \(0\)\
\-\ he\\:\\ 0\\.032317854258813325\ \(0\)\
\-\ however\\:\\ 0\\.0323025586574283\ \(0\)\
\-\ presented\\:\\ 0\\.03182558030601196\ \(0\)\
\-\ months\\:\\ 0\\.03176759590653518\ \(0\)\
\-\ significant\\:\\ 0\\.03151092903964064\ \(0\)\
\-\ enhancement\\:\\ 0\\.03141294460397439\ \(0\)\
\-\ t2\\:\\ 0\\.031399028388242954\ \(0\)\
\-\ one\\:\\ 0\\.031247271258516368\ \(0\)\
\-\ signal\\:\\ 0\\.030937532565069724\ \(0\)\
\-\ than\\:\\ 0\\.030937532565069724\ \(0\)\
\-\ symptoms\\:\\ 0\\.02986084721963138\ \(0\)\
\-\ physical\\:\\ 0\\.029592312053655204\ \(0\)\
\-\ increased\\:\\ 0\\.029512057806683735\ \(0\)\
\-\ upper\\:\\ 0\\.02916452188704009\ \(0\)\
\-\ noted\\:\\ 0\\.028936068361722436\ \(0\)\
\-\ tumor\\:\\ 0\\.028546368178340633\ \(0\)\
\-\ other\\:\\ 0\\.0283421470493524\ \(0\)\
\-\ small\\:\\ 0\\.028152093193029117\ \(0\)\
\-\ present\\:\\ 0\\.028004672762777794\ \(0\)\
\-\ lower\\:\\ 0\\.027888350398228505\ \(0\)\
\-\ exam\\:\\ 0\\.02747354114357375\ \(0\)\
\-\ after\\:\\ 0\\.026475669324423252\ \(0\)\
\-\ also\\:\\ 0\\.025670944659053622\ \(0\)\
\-\ which\\:\\ 0\\.024816209961141186\ \(0\)\
\-\ that\\:\\ 0\\.023683898906779327\ \(0\)\
\-\ by\\:\\ 0\\.02317609728112168\ \(0\)\
\-\ disease\\:\\ 0\\.02290902882099391\ \(0\)\
\-\ normal\\:\\ 0\\.022282978716556084\ \(0\)\
